Improvement in Risk Stratification in Transcatheter Aortic Valve Implantation Using a Combination of the Tumor Marker CA125 and the Logistic EuroSCORE

Translated title of the contribution: Improvement in Risk Stratification in Transcatheter Aortic Valve Implantation Using a Combination of the Tumor Marker CA125 and the Logistic EuroSCORE

Oliver Husser, Julio Núñez, Christof Burgdorf, Andreas Holzamer, Christian Templin, Thorsten Kessler, Vicente Bodi, Juan Sanchis, Costanza Pellegrini, Andreas Luchner, Lars S. Maier, Christof Schmid, Thomas F. Lüscher, Heribert Schunkert, Adnan Kastrati, Michael Hilker, Christian Hengstenberg

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Introduction and objectives Conventional risk scores have not been accurate in predicting peri- and postprocedural risk of patients undergoing transcatheter aortic valve implantation (TAVI). Elevated levels of the tumor marker carbohydrate antigen 125 (CA125) have been linked to adverse outcomes after TAVI. We studied the additional value of CA125 to that of the EuroSCORE in predicting long-term mortality after TAVI. Methods and results During a median follow-up of 59 weeks, 115 of 422 patients (27%) died after TAVI. Mortality was higher with elevated CA125 (> 30 U/mL) and EuroSCORE (> median) (47% vs 20%, P < .001 and 38% vs 16%, P < .001, respectively). In the multivariable analysis, CA125 (> 30 U/mL) remained an independent predictor of mortality (hazard ratio [HR], 2.16; 95% confidence interval [95%CI], 1.48-3.15; P < .001) and improved the predictive capability of the model (C-statistic: 0.736 vs 0.731) and the net reclassification index (51% 95%CI, 33-73) with an integrated discriminative improvement of 3.5% (95%CI, 0.5-8.4). A new variable (CA125-EuroSCORE) was created, with the combinations of the 2 possible binary states of these variables (+, elevated, -, not elevated; C1: CA125- EuroSCORE-; C2: CA125+ EuroSCORE-; C3: CA125- EuroSCORE+; C4: CA125+ EuroSCORE+). Patients in C1 exhibited the lowest cumulative mortality rate (14% [26 of 181]). Mortality was intermediate for C2 (CA125 > 30 U/mL and EuroSCORE ≤ median) and C3 (CA125 ≤ 30 U/mL and EuroSCORE > median): 27% (8 of 30) and 28% (37 of 131), respectively. Patients in C4 (CA125 > 30 U/mL and EuroSCORE > median) exhibited the highest mortality (55% [44 of 80], P-value for trend < .001). Conclusions CA125 offers additional prognostic information beyond that obtained by the EuroSCORE. Elevation of both markers was associated with a poor prognosis. Full English text available from: www.revespcardiol.org/en

Translated title of the contributionImprovement in Risk Stratification in Transcatheter Aortic Valve Implantation Using a Combination of the Tumor Marker CA125 and the Logistic EuroSCORE
Original languageEnglish
Pages (from-to)186-193
Number of pages8
JournalRevista Espanola de Cardiologia
Volume70
Issue number3
DOIs
StatePublished - 1 Mar 2017

Keywords

  • Logistic EuroSCORE
  • Risk prediction
  • Transcatheter aortic valve implantation
  • Tumor marker carbohydrate antigen 125

Fingerprint

Dive into the research topics of 'Improvement in Risk Stratification in Transcatheter Aortic Valve Implantation Using a Combination of the Tumor Marker CA125 and the Logistic EuroSCORE'. Together they form a unique fingerprint.

Cite this